SCHEMBL6785255

SCHEMBL6785255

CCOc1ccc(C(=O)N(Cc2cccnc2)Cc2ccccc2-c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ TRPM8 Q7Z2W7 1/20 0.51
▸ ALOX12 P18054 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ GPBAR1 Q8TDU6 4/20 0.47
▸ CCNC P24863 1/20 0.47
▸ CDK8 P49336 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.46
▸ PKM P14618 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ NPC1 O15118 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780767 0.85 ALDH1A1 (0.46) LMNATRPM8HTTNPSR1L3MBTL1
SCHEMBL6777732 0.79 LPAR1 (0.52) HTTNPSR1L3MBTL1ALDH1A1HPGD
SCHEMBL6780805 0.78 KMT2A (0.47) LMNAALOX12CYP1A2CYP3A4CYP2D6
SCHEMBL6780567 0.78 GPBAR1 (0.49) LMNAHTTNPSR1GPBAR1ALDH1A1
SCHEMBL6774110 0.78 SGMS2 (0.50) TRPM8HTTALDH1A1KMT2APOLB
SCHEMBL6778426 0.77 KMT2A (0.48) HTTNPSR1GPBAR1ALDH1A1HPGD
SCHEMBL6779730 0.75 GPBAR1 (0.44) HTTGPBAR1ALDH1A1KMT2AGAA
SCHEMBL6778233 0.74 HTT (0.51) LMNAHTTNPSR1GPBAR1ALDH1A1
SCHEMBL6779489 0.73 CLK1 (0.48) LMNANPSR1L3MBTL1GPBAR1ALDH1A1
SCHEMBL8429920 0.73 HPGDS (0.49) GPBAR1KMT2ALPAR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US claimed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US claimed
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT LMNA 4203/4885MAPK1 2199/4885TRPM8 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback